- Microscopic Polyangiitis Insights
- Posts
- Weekly Spotlight - 05.12.24
Weekly Spotlight - 05.12.24
Avacopan as an Add-On Therapy for ANCA-Associated Vasculitis: A Pharmacological Overview
Liam Ball
December 05, 2024 • Estimated Reading Time: 6 minutes
AllMyHealth, an accredited patient-led platform, has announced the start of its beta testing phase in England. The platform is designed to help those with rare diseases and chronic conditions manage their health data more effectively by centralising all health records in one place.
With AllMyHealth, you can securely fetch and store your records from all your healthcare providers, including GPs, NHS and private hospitals. You can easily browse your medical history, view your scans, share your records with clinicians and loved ones, and contribute to research effortlessly.
The platform is built on core values of patient empowerment, simplicity in healthcare management, and trust in its services.
"At AllMyHealth, we believe that every patient deserves to have control over their health journey. By launching our beta testing in England, we're taking a significant step towards revolutionising healthcare management and empowering individuals with rare diseases and chronic conditions to take charge of their records."
AllMyHealth is backed by Blenheim Chalcot, a leading global venture builder, and headquartered in Scale Space, part of Imperial College London, already serving over 50,000 patients.
Questions or feedback? Fill in the Feedback Form.
Community |
Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters! |
Latest News |
The study examines kidney disease in children with ANCA-associated vasculitis. By 12 months, most achieve inactive disease, although many suffer damage. Initial renal function strongly predicts future outcomes. Despite challenges, the findings offer hope for monitoring and supporting affected children, highlighting the need for early diagnosis and care. |
|
Avacopan as an Add-On Therapy for ANCA-Associated Vasculitis: A Pharmacological Overview |
Avacopan offers hope as an add-on treatment for ANCA-associated vasculitis, a severe disease affecting the lungs and kidneys. By inhibiting the C5a receptor, it reduces the need for glucocorticoids, lessening side effects and improving outcomes. This approach is promising for those facing relapses and complications. |
|
Two Decades of Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis |
Rituximab offers hope for patients with antineutrophil cytoplasmic antibody-associated vasculitis by reducing reliance on other treatments and lowering complications. Its ability to deplete B-lymphocytes shows promise for sustained remission, though dosage adjustments may be needed. Identifying relapse biomarkers could enhance future therapies, fostering optimistic patient outcomes. |
|
Rituximab treatment improves health-related quality of life in Bulgarian patients with ANCA-associated vasculitis. A study found significant enhancements in physical, mental, and social health, bringing them to normal levels. This provides hope and reassurance to patients and their families about the effectiveness of Rituximab therapy. |
Health Spotlight’s Microscopic Polyangiitis is a Contentive publication in the Healthcare division